By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Hereditary angioedema agents > Berinert > Berinert Dosage
Hereditary angioedema agents
https://themeditary.com/dosage-information/berinert-dosage-126.html

Berinert Dosage

Drug Detail:Berinert (Complement c1 esterase inhibitor [ kom-ple-ment-c1 es-ter-ase-in-hib-it-or ])

Generic Name: HUMAN C1-ESTERASE INHIBITOR 500[iU] in 10mL;

Dosage Form: injection

Drug Class: Hereditary angioedema agents

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

For intravenous use only.

Administer BERINERT at a dose of 20 International Units (IU) per kg body weight by intravenous injection. Doses lower than 20 IU/kg body weight should not be administered.

BERINERT is provided as a freeze-dried powder for reconstitution with the Sterile Water for Injection, USP provided. Store the vial in the original carton in order to protect from light. Do not freeze.

Preparation and Handling

  • ​Check the expiration date on the product vial label and on the administration kit. Do not use any component that is beyond the expiration date. Do not use if any components are damaged or opened.
  • ​Prepare and administer using aseptic techniques [see Dosage and Administration (2.2)].
  • ​Use the silicone-free syringe, provided, for administration of BERINERT [see How Supplied/Storage and Handling (16)].
  • After reconstitution and prior to administration, inspect BERINERT visually for particulate matter and discoloration. The reconstituted solution should be colorless, clear, and free from visible particles. Do not use if the solution is cloudy, discolored, or contains particulates.
  • The BERINERT vial is for single use only. BERINERT contains no preservative. Any product that has been reconstituted should be used promptly. The reconstituted solution must be used within 8 hours. Discard partially used vials.
  • Do not freeze the reconstituted solution.

Reconstitution and Administration

Each BERINERT vial containing 500 IU of C1 esterase inhibitor as a lyophilized concentrate for reconstitution with 10 mL of Sterile Water for Injection, USP provided.

Use either the Mix2Vial® transfer set provided with BERINERT [see How Supplied/Storage and Handling (16.1)] or a commercially available double-ended needle and vented filter spike.

Reconstitution

The procedures below are provided as general guidelines for the reconstitution and administration of BERINERT.

  1. Ensure that the BERINERT vial and diluent vial are at room temperature.
  2. Place the BERINERT vial, diluent vial and Mix2Vial transfer set on a flat surface.
  3. Remove the flip caps from the BERINERT and diluent vials. Wipe the vial stoppers with the alcohol swab provided. Allow to dry prior to opening the Mix2Vial transfer set package.
  4. Open the Mix2Vial transfer set package by peeling away the lid (Figure 1). Leave the Mix2Vial transfer set in the clear package.
    Figure 1

    Figure 1

  5. Place the diluent vial on a flat surface and hold the vial tightly. Grip the Mix2Vial transfer set together with the clear package and push the plastic spike at the blue end of the Mix2Vial transfer set firmly through the center of the stopper of the diluent vial (Figure 2).
    Figure 2

    Figure 2

  6. Carefully remove the clear package from the Mix2Vial transfer set. Make sure that you pull up only the clear package, and not the Mix2Vial transfer set (Figure 3).
    Figure 3

    Figure 3

  7. With the BERINERT vial placed firmly on a flat surface, invert the diluent vial with the Mix2Vial transfer set attached and push the plastic spike of the transparent adapter firmly through the center of the stopper of the BERINERT vial (Figure 4). The diluent will automatically transfer into the BERINERT vial.
    Figure 4

    Figure 4

  8. With the diluent and BERINERT vial still attached to the Mix2Vial transfer set, gently swirl the BERINERT vial to ensure that the BERINERT is fully dissolved (Figure 5). Do not shake the vial.
    Figure 5

    Figure 5

  9. With one hand, grasp the BERINERT-side of the Mix2Vial transfer set and with the other hand grasp the blue diluent-side of the Mix2Vial transfer set and unscrew (counter clockwise) the set into two pieces (Figure 6).
    Figure 6

    Figure 6

  10. Carefully look at reconstituted solution in each vial of BERINERT. It should be colorless, clear, and free from visible particles. Do not use the vial if the liquid looks cloudy, contains particles, or has changed color. Do not use if the expiration date on the label has expired.
  11. Draw air into the empty, sterile, silicone-free syringe provided. While the BERINERT vial is upright, screw the syringe to the Mix2Vial transfer set. Inject air into the BERINERT vial. While keeping the syringe plunger pressed, invert the system upside down and draw the concentrate into the syringe by pulling the plunger back slowly (Figure 7). If BERINERT is not immediately used, please store reconstituted solution in the vial.
    Figure 7

    Figure 7

  12. Now that the concentrate has been transferred into the syringe, firmly grasp the barrel of the syringe (keeping the plunger facing down) and unscrew (counter clockwise) the syringe from the Mix2Vial transfer set (Figure 8). Attach the syringe to a suitable intravenous administration set.
    Figure 8

    Figure 8

  13. If patient requires more than one vial, a new unused Mix2Vial transfer set and a new silicone-free syringe should be used for each BERINERT vial.
  14. Do not refrigerate after reconstitution. When reconstitution is carried out using aseptic technique, administration may begin within 8 hours, provided the solution has been stored at up to 30°C (86°F). Do not refrigerate or freeze the reconstituted solution. Only store the reconstituted solution in the vial.
Administration
  • Do not mix BERINERT with other medicinal products. Administer BERINERT by a separate infusion line.
  • Use aseptic technique when administering BERINERT.
  • Use the silicone-free syringe provided in the administration kit [see How Supplied/Storage and Handling (16)].
  • Follow recommended venipuncture guidelines for initiating intravenous therapy.
  • Administer BERINERT by slow intravenous injection at a rate of approximately 4 mL per minute. Please refer to the illustration in step 6 of the self-administration section in the Patient Product Information (PPI) section.
  • For self-administration, provide the patient with instructions and training for intravenous injection outside of a clinic setting so patients may self-administer BERINERT upon recognition of symptoms of an HAE attack [see Patient Counseling Information (17)].
  • After administration, immediately discard any unused product and all used disposable supplies in accordance with local requirements.
Share this Article
Latest News
Medical News

Shingles vaccine may lower heart disease risk by up to 8 years

May 09, 2025
Obesity, unhealthy lifestyles may cause heart to age by 5–45 years
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by